Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients-Reference-Cited by-同舟云学术

Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients

Published:2024-08-01 Issue:6 Volume:39 Page:435-440
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Chen Yibo¹²³⁴⁵,Zhang Tianyi⁶,Zhang Rui¹,Cao Xuchen²³⁴⁵^ORCID

Affiliation:

1. Department of General Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.

2. The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.

3. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.

4. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

5. Tianjin's Clinical Research Center for Cancer, Tianjin, China.

6. School of Basic Medical Sciences, Shandong University, Jinan, China.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2023.0175

Reference24 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study

3. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond

4. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

5. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond